Alpha Cognition Inc. (ACOG)
Nasdaq: ACOG · Biological Products, (No Diagnostic Substances) · Grapevine, TX · filing with the SEC since 2015
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 31, 2026 | Mar 31, 2025 | · |
| Revenue | 10,220,275 | · | · |
| For lenders | |||
| Provision for credit losses | · | 55,000 | · |
| Cost of revenue | 603,400 | · | · |
| Research and development | 1,867,972 | 3,920,412r | 4,883,973 |
| Selling, general and administrative | 29,076,123 | 8,012,230 | · |
| General and administrative | · | 7,942,112 | 5,054,120 |
| Total operating expenses | 32,880,964 | 12,012,517r | 9,938,093 |
| Total costs and expenses | 32,880,964 | 12,012,517 | · |
| Operating income | -22,660,689 | -12,012,517r | -9,938,093 |
| Interest expense | · | 105,273 | 17,516 |
| Interest and investment income | · | 161,664 | 6,804 |
| Interest income (expense), net | 1,899,370 | 161,664 | · |
| Total non-operating income (expense) | 1,990,814 | -2,776,210 | -3,825,565 |
| Net income | -20,669,875 | -14,788,727r | -13,763,658 |
| Net income to common shareholders | -20,669,875 | -14,788,727r | -13,763,658 |
| Earnings per share, basic | -1.17 | -2.04r | -3.84 |
| Earnings per share, diluted | -1.18 | -2.04r | -3.84 |
| Weighted average shares, basic | 17,680,597 | 7,247,864 | 3,585,440 |
| Weighted average shares, diluted | 17,681,429 | 7,247,864 | 3,585,440 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesProvision for credit losses set aside for loans that may not be repaid
us-gaap:ProvisionForLoanLeaseAndOtherLossesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:CostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding